vrdn: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	20,833	9,976
Net increase in cash and cash equivalents	70,053	17,730
Cash and cash equivalents at beginning of period	99,594	-
Cash and cash equivalents at end of period	169,647	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	20,833	9,976
Net increase in cash and cash equivalents	70,053	17,730
Cash and cash equivalents at beginning of period	99,594	-
Cash and cash equivalents at end of period	169,647	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Viridian Therapeutics, Inc. DE (VRDN)